In the premarket trading session, Intellia Therapeutics Inc. (NTLA) stock has had its shares advance by 57.72% to trade at the price of $140.10 at the last check. NTLA stock has closed its previous sessing with a gain on Monday for 2.29% at $88.83. The NTLA stock traded a volume of 2.61 million shares. In the past year up to date, the NTLA stock have risen by 313.36% and in the past week, they jumped up by 17.00%. In the past three and six months, the stock has surged by 37.23% and added 40.22%. Furthermore, the company is currently valued in the market at $5.92 billion and has 67.18 million outstanding shares.
Dwelling deeper into the operations of Intellia Therapeutics Inc.
Intellia Therapeutics Inc. is a biotechnology company that specifically focuses on the research, development and application of genome editing. The company focuses on the utilization of different kinds of for the analysis and testing of gene editing and studying. These gene editing applications will then be used in the development of therapeutics. NTLA stock uses tools like Clustered, Regularly Interspaced Short Palindromic Repeats which is shortly known as CRISPR which is associated with the Cas9 system. One of the recent programs highlighted in the company are the Vivo programs which include the trial for the treatment of thansthyretin amyloidosis known as NTLA-2001. The program is in phase 1 clinical trial and the NTLA-2002 which is being developed from the treatment of hereditary angioedema, along with the other liver-focused programs. These include hemophilia A and B, Hyperoxaluria Type 1, and alpha-1 antutrypsin deficiency.
NTLA stock focuses on the programs exclusively and also partners up with potential strategically beneficial institutes, clinics and biotech firms for developing, discovering, designing, and clinically testing treatments and therapeutics. This includes companies like Novartis Institutes for BioMedical Therapeutics, Inc. with which it focuses on for the development and engineering of hematopoietic stem cells in order to treat sickle cell diseases. The partnership is based on collaboration and licensing agreement. The company also focuses on the co-development of potential treatments for hemophilia A and B, and Ospedale San Raffaelewith Regeneron Pharmaceuticals Inc. Intellia Therapeutics was previously known as AZRN till July 2014 and NTLA stock was incorporated in 2014 as well. The headquarter is based in Cambridge Massachusetts.
Major advancement in the CRISPR genome editing done in collaboration with Regeneron Pharmaceuticals inc.
The company has recently made a breakthrough in the Phase 1 Trial of the vivo CRISPR genome editing in humans by finding and observing data that it is the first of its kind to support safety and efficacy of the gene editing. The clinical data specifically showcases deep reduction in disease-causing protein after single infusion of NTLA-2001. The empirical result of the efficacy displayed an 87% reduction in serum TTR through a 0.3 mg/kg dose of NTLA 2001 which furthered to a 96% max reduction after 27 days.
During these 28 days, there were no serious deviations from expected results or adverse events observed for the first six patients. The company has now decided to add this data in The New England Journal of Medicine and also already presented the data in the 2021 Peripheral Nerve Society (PNS) on 26th June 2021, Saturday.